Edgar Filing: INVIVO CORP

e10vq

U.S. Securities and Exchange Commission

Washington, D.C. 20549

FORM 10-Q


x		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

		FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2002

		OR

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

COMMISSION FILE NUMBER 0-15963

INVIVO CORPORATION

(Exact name of Registrant as specified in its charter)


DELAWARE		77-0115161
(State or other jurisdiction Of incorporation)		(IRS Employer Identification No.)

4900 HOPYARD RD. SUITE 210, PLEASANTON, CALIFORNIA		94588
(Address of principal executive offices)		(Zip Code)

TELEPHONE: (925) 468-7600
(Registrant’s telephone number)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

The number of shares outstanding of the issuer’s Common Stock, par value $.01 per share, at February 3, 2002 was 4,514,199 shares.

TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION
	ITEM 1. FINANCIAL STATEMENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
	ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
	ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
	ITEM 4. CONTROLS AND PROCEDURES
PART II — OTHER INFORMATION
	ITEM 1: LEGAL PROCEEDINGS:
	ITEM 2: CHANGES IN SECURITIES:
	ITEM 3: DEFAULTS UPON SENIOR SECURITIES:
	ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITIES HOLDERS:
	ITEM 5: OTHER INFORMATION:
	ITEM 6: EXHIBITS AND REPORTS ON FORM 8-K
SIGNATURES
CHIEF EXECUTIVE OFFICER CERTIFICATION
CHIEF FINANCIAL OFFICER CERTIFICATION
Exhibit 10.4
Exhibit 99.1

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

INVIVO CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS


			(UNAUDITED)
			December 31,		June 30,
Assets			2002		2002

Current assets:
	Cash and cash equivalents		$	877,600		1,005,700
	Restricted cash			1,356,300		1,520,900
	Short-term investments			26,252,300		27,344,400
	Trade receivables, less allowance for doubtful accounts of $552,300 as of December 31, 2002 and $330,500 as of June 30, 2002			11,943,800		10,724,600
	Inventories			8,103,700		6,430,400
	Deferred income taxes			1,054,700		837,800
	Prepaid expenses and other current assets			475,400		236,700

		Total current assets		50,063,800		48,100,500
Property and equipment, net				5,667,400		5,476,000
Intangible assets				7,037,000		7,037,000
Other assets				176,200		144,200

			$	62,944,400		60,757,700

Liabilities and Stockholders’ Equity
Current liabilities:
	Accounts payable		$	2,659,400		1,778,300
	Accrued expenses			5,976,000		6,045,900
	Current portion of long-term debt			113,300		113,300
	Income taxes payable			616,900		1,325,100

		Total current liabilities		9,365,600		9,262,600
Long-term debt, excluding current portion				1,407,200		1,463,900
Deferred income taxes				550,400		550,400

		Total liabilities		11,323,200		11,276,900

Commitments and contingencies
Stockholders’ equity:
	Common stock, $.01 par value; authorized shares totaling 20,000,000; issued and outstanding shares totaling 4,483,699 as of December 31, 2002 and 4,434,899 as of June 30, 2002			44,800		44,300
	Additional paid-in capital			27,203,900		26,701,000
	Retained earnings			24,274,000		22,720,400
	Accumulated other comprehensive income			98,500		14,300

		Total stockholders’ equity		51,621,200		49,480,800

			$	62,944,400		60,757,700

INVIVO CORPORATION AND SUBSIDIARIES
Consolidated Statements of Income
(Unaudited)


				Three Months Ended						Six Months Ended
				December 31,						December 31,

				2002			2001			2002			2001

Sales				$	12,325,900			10,246,400			23,376,800			19,819,100
Cost of goods sold					6,118,500			4,646,800			11,378,900			9,191,700

			Gross profit		6,207,400			5,599,600			11,997,900			10,627,400

Operating expenses:
	Selling, general, and administrative				4,409,600			3,888,900			8,559,400			7,531,200
	Research and experimental				753,400			857,500			1,553,000			1,568,400

			Total operating expenses		5,163,000			4,746,400			10,112,400			9,099,600

			Income from operations		1,044,400			853,200			1,885,500			1,527,800
Other income (expense):
	Interest income				221,900			50,300			373,400			121,700
	Interest expense				(14,700	)		(13,600	)		(31,800	)		(52,000	)
	Other, net				29,100			—			29,100			—

			Income from continuing operations before income taxes		1,280,700			889,900			2,256,200			1,597,500
Income tax expense					409,900			301,700			702,600			541,600

			Net income from continuing operations	$	870,800			588,200			1,553,600			1,055,900

Discontinued operations:
		Income from discontinued operations net of income tax of $111,100 and $249,100			—			178,200			—			413,000

			Net income	$	870,800			766,400			1,553,600			1,468,900

Basic net income per share data:
Continuing operations				$	0.19			0.13			0.35			0.24
Discontinued operations					—			0.04			—			0.09

Basic net income per common share				$	0.19			0.17			0.35			0.33

Weighted-average common shares outstanding (basic)					4,477,554			4,424,119			4,470,733			4,423,684

Diluted net income per share data:
Continuing operations					0.19			0.13			0.33			0.23
Discontinued operations					—			0.04			—			0.09

Diluted net income per common share				$	0.19			0.17			0.33			0.32

Weighted-average common shares outstanding (diluted)					4,675,774			4,593,068			4,686,244			4,552,362

See accompanying notes to consolidated financials

INVIVO CORPORATION AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(Unaudited)
For the Six Months Ended December 31,


					2002			2001

Cash flows from operating activities:
	Net income				$	1,553,600			1,468,900
	Adjustments to reconcile net income to net cash provided by operating activities:
		Depreciation and amortization				555,200			454,100
		Deferred income taxes				(216,900	)		(71,500	)
		Changes in operating assets and liabilities:
			Trade receivables			(1,204,000	)		1,777,100
			Inventories			(1,645,100	)		39,400
			Prepaid expenses and other current assets			(238,700	)		(36,800	)
			Accrued expenses			(69,900	)		61,200
			Accounts payable			881,100			(657,900	)
			Income taxes payable			(708,200	)		(136,100	)
			Current liabilities of discontinued operations			—			(243,700	)
			Current assets of discontinued operations			—			290,000

				Net cash (used in) provided by operating activities		(1,092,900	)		2,944,700

Cash flows from investing activities:
	Sale (purchase) of short-term investments, net					1,161,100			(631,100	)
	Restricted cash					164,600			—
	Capital expenditures					(774,800	)		(1,042,800	)
	Other assets					(32,000	)		—
	Net investing activities of discontinued operations					—			16,200

				Net cash provided by (used in) investing activities		518,900			(1,657,700	)

Cash flows from financing activities:
	Exercise of stock options					502,600			20,100
	Payments under long-term debt and capital leases					(56,700	)		(70,700	)

				Net cash provided by (used in) financing activities		445,900			(50,600	)

Net (decrease) increase in cash and cash equivalents						(128,100	)		1,236,400
Cash and cash equivalents at beginning of period						1,005,700			270,100

Cash and cash equivalents at end of period					$	877,600			1,506,500

See accompanying notes to consolidated financial statements.

INVIVO CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

GENERAL

The consolidated balance sheet as of December 31, 2002 and the related consolidated statements of income for the three and six month periods ended December 31, 2002 and 2001, and the consolidated statements of cash flows for the three and six month periods ended December 31, 2002 and 2001 are unaudited. The consolidated financial statements reflect, in the opinion of management, all adjustments necessary to present fairly the financial position and results of operations as of the end of and for the periods indicated. Interim results are not necessarily indicative of results for a full year.

The financial statements and notes are presented as permitted by Form 10-Q, and do not contain certain information included in the Company’s annual consolidated financial statements and notes.

SEGMENT INFORMATION

The Company has adopted the provisions of Statement of Financial Accounting Standards (SFAS) No. 131, Disclosure About Segments of an Enterprise and Related Information. SFAS 131 establishes standards for the reporting by public business enterprises of information about operating segments, products and services, geographic areas, and major customers. The method for determining what information to report is based on the way that management organizes the operating segments within the Company for making operating decisions and assessing financial performance. As a result of the sales of Sierra Precision and Lumidor Safety Corporation, previously wholly-owned subsidiaries of the Company operating in the Company’s industrial instrumentation segment, the Company currently operates in one segment.

DEBT AND BANK BORROWINGS

The Company renewed its $1,000,000 bank line of credit on January 1, 2003. The Company’s revolving bank line of credit is unsecured. At December 31, 2002, $1,000,000 was available under the line of credit.

COMPREHENSIVE INCOME

The components of comprehensive income, net of tax, are as follows:


	THREE MONTHS ENDED					SIX MONTHS ENDED
	DECEMBER 31,					DECEMBER 31,

	2002		2001			2002		2001

Net income	$	870,800	$	766,400		$	1,553,600	$	1,468,900
Change in unrealized gain on short-term investments		41,000		—			69,000		—
Change in foreign currency translation		8,600		(43,400	)		15,200		(10,800	)

Comprehensive Income	$	920,400	$	723,000		$	1,637,800	$	1,458,100

NET INCOME PER COMMON SHARE

The following table presents the calculation for basic and diluted net income per common share:


		THREE MONTHS ENDED				SIX MONTHS ENDED
		DECEMBER 31,				DECEMBER 31,

		2002		2001		2002		2001

BASIC:
	Weighted average common Shares outstanding		4,477,554		4,424,119		4,470,733		4,423,684

	Net Income	$	870,800	$	766,400	$	1,553,600	$	1,468,900

	Basic net income per common share	$	0.19	$	0.17	$	0.35	$	0.33

DILUTED:
	Weighted average common Shares outstanding (basic)		4,477,554		4,424,119		4,470,733		4,423,684
	Dilutive stock options		198,220		168,949		215,511		128,678

	Weighted average common Shares outstanding (diluted)		4,675,774		4,593,068		4,686,244		4,552,362

	Net Income	$	870,800	$	766,400	$	1,533,600	$	1,468,900

	Diluted net income per common share	$	0.19	$	0.17	$	0.33	$	0.32

DISCONTINUED OPERATIONS

Sierra Precision

On May 10, 2002, the Company completed its sale of substantially all of the assets and the transfer of certain liabilities of Sierra Precision, a wholly-owned subsidiary of the Company. The final sales price was approximately $4.9 million. Excluded from the transaction were substantially all the liabilities of Sierra Precision. In addition, the Company entered into an agreement to not compete with the business of Sierra Precision for a period of three years. Sierra Precision’s operating results have been segregated and reported as discontinued operations in the accompanying consolidated statements of income and cash flows, and related notes for the three and six months ended December 31, 2001. Revenue from the discontinued operations of Sierra Precision for the three and six months ended December 31, 2001 was $1,477,300 and $3,375,800, respectively. Income, net of income tax, from the discontinued operations of Sierra Precision for the three and six months ended December 31, 2001 was $55,300 and $197,100, respectively.

Lumidor Safety Corporation

On May 30, 2002, the Company sold substantially all of the assets and transferred certain liabilities of Lumidor Safety Corporation (“Lumidor”), a wholly-owned subsidiary of the Company. The final sales price was approximately $12 million, of which $1.35 million is being held in escrow for a period of one year to secure indemnification obligations of Lumidor. In addition, the Company entered into an agreement not to compete with the business of Lumidor for a period of five years. Lumidor’s operating results have been segregated and reported as discontinued operations in the accompanying consolidated statements of income and cash flows, and related notes for the three and six months ended December 30, 2001. Revenue from the discontinued operations of Lumidor for the three and six months ended December 31, 2001 was $1,817,500 and $3,709,600, respectively. Income, net of income tax, from the discontinued operations of Lumidor for the three and six months ended December 31, 2001 was $122,900 and $215,900, respectively.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS

THREE AND SIX MONTH PERIODS ENDED DECEMBER 31, 2002 AND 2001

Sales

Sales of $12,325,900 for the second quarter ended December 31, 2002 increased 20.3% compared to sales of $10,246,400 for the second quarter ended December 31, 2001. Sales for the six months ended December 31, 2002 increased 18.0% to $23,376,800 compared with $19,819,100 for the comparable period last year. The increase was due to continued growth in sales of the Company’s magnetic resonance imaging, or MRI, vital signs monitors along with an increase in sales of general patient monitoring products. The increase in sales of general patient monitoring products was primarily due to sales of three new products, the “M12” bedside monitor introduced in the first quarter of fiscal 2003, the “Centurion 2000” central station monitoring system introduced in the fourth quarter of fiscal 2002 and the “Magnitude AS” anesthesia delivery system for MRI introduced in the second quarter of fiscal 2003.

Gross Profit

The gross profit margin decreased for the three months ended December 31, 2002 to 50.4% from 54.7% and decreased to 51.3% from 53.6% for the six months ended December 31, 2002 as compared to the comparable prior year periods. The decreases for the quarter and the six months ended December 31, 2002 were primarily attributable to sales of the “Magnitude AS” anesthesia delivery system for MRI. The “Magnitude AS” is sold under an exclusive distributor agreement with an original equipment manufacturer, Draeger Medical, Inc., and has inherently lower gross profit margins than the other vital signs monitors sold by the Company. The Company maintained its gross profit margin on the MRI vital signs monitor for the three and six months ended December 31, 2002.

Operating Expenses

Selling, general and administrative expenses for the three and six month periods ended December 31, 2002 increased 13.4% or $520,700 and 13.7% or $1,028,200, respectively, from the previous fiscal periods. Selling, general and administrative expenses were 35.8% and 36.6% of sales for the three and six month periods ended December 31, 2002 compared with 38.0% for the comparable periods in fiscal 2002. The increases in these expenditures for the three and six months ended December 31, 2002 were primarily due to increased selling expenses, as sales commissions increased on the higher sales volume, along with higher administrative expenses in support of the increase in sales.

Research and experimental expenses for the three and six month periods ended December 31, 2002 decreased 12.1% or $104,100 and 1.0% or $15,400, respectively, from the previous fiscal periods. Research and experimental expenses were 6.1% and 6.6% of sales for the three and six month periods ended December 31, 2002 compared to 8.4% and 7.9% for the comparable periods in fiscal 2002. Substantial material expenditures for the development of the next generation vital signs monitors, the timing of which occurred primarily in the prior fiscal year’s second quarter, accounted for the difference in research and experimental spending levels as compared to the second quarter of fiscal 2003. The Company plans to continue its efforts in developing new products and enhancing its existing ones and expects future research and experimental expenditures as a percentage of sales to be in the range of the first half of fiscal 2003 levels.

Other Income and Expense

Interest income was $221,900 for the second quarter of fiscal 2003 as compared to $50,300 for the prior year period. For the first six months of fiscal 2003 interest income was $373,400 as compared to $121,700 for the prior year period. These increases in interest income were due to the larger cash and short-term investment balances in the current year quarter as compared to the prior year as a result of the sales of Sierra Precision and Lumidor in the second half of fiscal 2002. The $29,100 in other income for the second quarter of fiscal 2003 was related to capital gains from short-term investments.

Provision for Income Taxes

The effective tax rate for the first six months of fiscal 2003 was 31.1% as compared to 33.9% for the comparable prior year period. The decrease in the effective rate was primarily due to the effect of federal tax-exempt interest income from short-term investments.

LIQUIDITY AND CAPITAL RESOURCES

Working capital at December 31, 2002 increased to $40,695,000 from $38,837,900 at June 30, 2002. Net cash used in operating activities was $1,092,900 for the six months ended December 31, 2002 compared with $2,944,700 provided by operating activities for the six months ended December 31, 2001. This increase in net cash used in operating activities was largely the result of changes in operating assets and liabilities, particularly accounts receivable, inventories and income taxes payable.

Capital expenditures were $774,800 for the first six months of fiscal 2003 compared to $1,042,800 for the prior year period. Capital expenditures were primarily related to sales demonstration equipment for the medical business sales force.

With the sales of the Company’s gas detection and oxygen monitoring businesses in the second half of fiscal 2002, the Company has substantially more cash on its balance sheet than it had in the past. While the Company believes it is advantageous to maintain cash for potential acquisitions of complementary businesses or product lines, it further determined that its current cash balance represented more cash than it would likely require in the foreseeable future for these purposes. As a result, the Company’s Board of Directors concluded that using a portion of the Company’s cash for a stock buyback was the best way to utilize this resource to enhance stockholder value. Accordingly, on January 13, 2003, the Company commenced a tender offer to purchase for cash 650,000 shares of its common stock at a price of $15.00 per share. The planned expiration date for the offer is February 11, 2003. If this offer is fully subscribed, the Company would retain over $30 million in net working capital. The Company believes that this amount would be more than sufficient to support its ongoing operating activities, including the continued investment in product development. The Company also believes that the remaining cash balance, along with its borrowing capacity and the availability of its publicly traded equity securities, likely would be sufficient to support any opportunities the Company may identify to acquire complementary businesses and product lines.

The Company renewed its $1,000,000 revolving bank line of credit on January 1, 2003. The line of credit is unsecured. At December 31, 2002, $1,000,000 was available under the line of credit.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and judgments that affect its reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis the Company evaluates its estimates, including those related to allowance for doubtful accounts, inventory reserves, warranty obligations, intangible assets, income taxes, revenue recognition and contingencies and litigation. The estimates are based on the information that is currently available to the Company and on various other assumptions that management believes to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.

For a discussion of the Company’s critical accounting policies, please see “Critical Accounting Policies and Estimates” in Item 7 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2002.

RECENT ACCOUNTING PRONOUNCEMENTS

In August 2001, the FASB issued Statement No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets” (SFAS 144). SFAS 144 supersedes SFAS 121, “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of”, and provides new rules on asset impairment and a single accounting model for long-lived assets to be disposed of. Although retaining many of the fundamental recognition and measurement provisions of SFAS 121, the new rules significantly change the criteria that would have to be met to classify an asset as held-for-sale. The new rules also supersede the provisions of Accounting Principles Board Opinion No. 30, “Reporting the Results of Operations-Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions,” with regard to reporting the effects of a disposal of a segment of a business and require expected future operating losses from discontinued operations to be displayed in discontinued operations in the period(s) in which the losses are incurred. SFAS 144 is effective in fiscal 2003, and is not expected to have a material impact on the Company’s consolidated financial statements.

In April 2002, the FASB issued SFAS No. 145, “Rescission of FASB Statements No. 4, 44 and 64, Amendment of FASB Statement No. 13, and Technical Corrections” (SFAS 145). SFAS 145 revises the criteria for classifying the extinguishments of debt

as extraordinary and the accounting treatment of certain lease modifications. SFAS 145 is effective in fiscal 2003, and is not expected to have a material impact on the Company’s consolidated financial statements.

On July 30, 2002, the FASB issued SFAS No. 146, “Accounting for Costs Associated with Exit or Disposal Activities” (SFAS 146). SFAS 146 establishes accounting guidelines for the recognition and measurement of a liability for the cost associated with an exit or disposal activity initially at its fair value in the period in which the liability is incurred, rather than at the date of a commitment to an exit or disposal plan. This standard is effective January 1, 2003 for all exit or disposal activities initiated after that date and is not expected to have a material impact on the Company’s consolidated financial statements.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements regarding the Company’s plans, expectations, estimates and beliefs. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The Company is not obligated to update or revise these forward-looking statements to reflect new events or circumstances. Factors that could cause actual results, events or circumstances to differ from forward-looking statements made in this report include those set forth in the following “Risk Factors” section.

RISK FACTORS

THE COMPANY IS DEPENDENT ON A CONCENTRATED LINE OF PRODUCTS

The Company’s future financial performance will be dependent on its patient monitor product line, which includes a limited number of products. In the MRI monitoring market, the growth of the market for the Company’s MRI monitors is heavily dependent on the continued acceptance of MRI technology as a diagnostic tool. In the general patient monitoring market, future growth of the Company’s Millennia and M12 monitors is dependent on the Company’s ability to further penetrate an already competitive market.

In addition, the recent consolidation in the medical care provider market has resulted in a number of very large purchasers of medical devices. These large purchasers typically prefer to establish relationships with medical device manufacturers that have broad and diverse product lines.

The failure of the Company’s products to continue to gain market acceptance or a continued consolidation of the medical care provider market could have a material adverse effect on the Company’s business and results of operations.

THE COMPANY FACES SUBSTANTIAL LEVELS OF COMPETITION

The Company has encountered and will likely continue to encounter significant competition in the sale of its products. The Company’s general patient monitoring competitors include a number of large multinational corporations. Some of these competitors may be able to adapt more quickly to new or emerging technologies and changes in customer requirements, or to devote greater resources to the development, promotion and sale of their products than the Company can. In the MRI patient monitoring market, the Company has enjoyed a significant first-to-market advantage over its competitors. However, competitors have introduced products that compete with the Company’s MRI vital signs monitoring products. In addition, as the market for MRI vital signs monitoring products expands it may attract competitors with greater resources.

Additionally, competition may increase if new companies enter the Company’s markets or if existing competitors expand their product lines or intensify efforts within existing product lines. The introduction of competitive products may result in a decrease in the Company’s market share and in a decrease in the prices at which the Company is able to sell its products. The Company’s market share could also be adversely affected by increasing concentration in the medical care provider market. Any decrease in the Company’s market share or decrease in the prices at which the Company is able to sell its products could have a material adverse effect on its business and results of operations.

THE COMPANY’S FINANCIAL RESULTS MAY FLUCTUATE

The Company’s financial results may fluctuate significantly from period to period because of a variety of factors, many of which are beyond its control. These factors include:

•		increased competition, including possible future competition in the MRI monitor market

•		changes in the Company’s pricing policies and those of its competitors

•		changes in the Company’s operating expenses or capital expenditures

•		timing and market acceptance of new and upgraded product introductions by the Company and its competitors

•		introduction of alternative technologies by the Company and its competitors

•		effect of potential acquisitions

•		other general economic factors

Fluctuations caused by these and other factors could have a material adverse effect on the Company’s business and results of operations.

THE COMPANY IS SUBJECT TO A SIGNIFICANT RISK OF NEW LAWS RELATED TO HEALTH CARE

Changes in the law or new interpretations of existing laws may have a significant effect on the Company’s costs of doing business and the amount of reimbursement the Company receives from both government and third-party payors. In addition, economic forces, regulatory influences and political initiatives are subjecting the health care industry to fundamental changes. Federal, state and local government representatives are likely to continue to review and assess alternative health care delivery systems and payment methods. The Company expects ongoing public debate on these issues. Any of these efforts or reforms could have a material adverse affect on the Company’s business and results of operations.

THE COMPANY’S BUSINESS IS SUBJECT TO TECHNOLOGICAL CHANGE AND INTRODUCTION OF NEW PRODUCTS

Technological change, evolving industry standards and new product introductions and enhancements characterize the markets for the Company’s products. Many of the Company’s existing products and products under development are technologically innovative, and therefore require significant planning, design, development and testing. These activities require the Company to make significant capital commitments and investments. In addition, industry standards may change on short notice and new products and technologies may render existing products and technologies uncompetitive. Additionally, the products that the Company is currently developing, and those that the Company develops in the future, may not be technologically feasible or accepted by the marketplace or they may not be completed in an acceptable time frame. Technological change could prevent the Company from achieving the benefits it expects form research initiatives and could also result in a loss from existing products.

THE COMPANY CURRENTLY IS INVOLVED IN LEGAL PROCEEDINGS

The Company’s medical device subsidiary, Invivo Research, was one of two third-party defendants named in a lawsuit in June of 1994 by Southern Nevada Surgical Center and Surgex Southern Nevada, Inc. in Nevada State District Court. The underlying action in this matter stemmed from an incident involving a surgical patient undergoing a procedure at the Southern Nevada Surgical Center. The patient suffered a serious permanent brain injury. A lawsuit was filed on behalf of the patient against the surgical center and the anesthesiologist who monitored the patient. The defendants in that action made a substantial settlement to the patient. Southern Nevada Surgical Center (“SNSC”) and Surgex were seeking indemnity and contribution of approximately $14 million from the manufacturer of the anesthetic gas machine and Invivo Research, which manufactured the vital signs monitor used in this procedure. SNSC and Surgex alleged that both the anesthetic gas machine and the vital signs monitor were defective. The Company believes that the vital signs monitor operated properly and was properly designed for its intended function.

On August 18, 1999, the Nevada District Court granted the Company’s Motion to Dismiss for Failure to Prosecute. The Order granted dismissal of the SNSC and Surgex contribution claims, without prejudice, based upon Nevada law that provides that an action must be brought to trial within five years of the date of the filing of the original action. The dismissal is being appealed.

In April of 1997, the plaintiff’s insurer, CNA, filed an action with identical causes in the same Nevada State Court. This second action was removed by the Company to U.S. District Court. The action by CNA was dismissed by the District Court on January 19, 2000 as the District Court found CNA did not have standing as the real party of interest. CNA appealed the decision to the Ninth Circuit Court of Appeals. A three-member panel of the Ninth Circuit reversed the dismissal and remanded the case back to Federal District Court on July 30, 2001. The Company appealed this decision and requested a decision from the full panel of the Ninth Circuit. The Ninth Circuit, without issuing an opinion, unanimously voted to deny the Petition for Rehearing in this matter. The action was remanded to the U.S. District Court for further proceedings.

In December of 2002, the Company’s insurer agreed to globally settle the U.S. District Court action and Nevada District Court action for an amount within the insurance policy’s applicable limits.

In January of 2003, the U.S. District Court granted the Company’s Motion for Summary Judgment, which the Company filed in October 2002, and the matter was dismissed. The Company believes that CNA will appeal the dismissal.

In November, 1999, four individuals previously employed by the Company’s Invivo Research subsidiary filed a multi-plaintiff lawsuit against the Company in the Middle District Court of Florida alleging violations of the Age Discrimination in Employment Act. Since this filing, three additional individuals have chosen to “opt-in” to this case, one of the individuals has subsequently voluntarily dismissed all claims with prejudice and a second individual has filed a voluntary motion for dismissal from the case. The remaining plaintiffs are claiming entitlement to back pay and front pay in an aggregate amount of approximately $3 million. If they are successful, they would be also be entitled to liquidated (double) damages with respect to back pay, to their attorneys’ fees and costs and to prejudgment interest. The Company believes that Invivo Research has substantial defenses to the plaintiffs’ allegations and intends to defend itself vigorously in this matter. The Company further believes that even if the plaintiffs were successful in pursuit of their claims the proper amount of damages would be substantially less than the amount alleged. The trial in this matter is currently set to begin in the second quarter of 2003.

In addition to the litigation described above, the Company is also currently a defendant in other litigation matters and may from time to time be subject to new litigation and third party claims. Litigation is by its nature costly and may divert management’s attention, either of which could adversely affect the Company’s operating results. In addition, if any current or future litigation is determined adversely, the Company’s operating results and financial condition could be adversely affected.

THE COMPANY FACES PRODUCT LIABILITY AND PRODUCT RECALL RISKS

With respect to all of its products, and particularly its medical devices, the Company faces the risk of potentially large product liability claims. The malfunction or misuse of its products could potentially result in serious harm to a patient. In addition, the Company may be required to indemnify its distributors and customers for similar claims made against them.

Claims could be made against the Company even if its products did not contribute to the injury that was sustained. Frequently, the Company’s products are used with products developed by other manufacturers. Even if its products are not the cause of the injury, the Company may not be able to prove that some other product malfunction or human error caused a claimant’s injury.

The Company has had product liability claims made against it in the past and may have further claims made against it in the future. While the Company is insured for certain product liability claims, not all claims will be covered and the level of its insurance may not be sufficient to protect it from the full amount of a successful claim. In addition, the Company may not be able to obtain adequate amounts of insurance at an acceptable cost. Claims made against the Company that are not insured, or that exceed the amount of the Company’s coverage, could have a material adverse effect on its business and results of operations.

Similarly, the Company’s products are subject to the potential of being recalled by government agencies for actual or potential deficiencies or problems. Any such recall would likely be expensive and would have a material adverse effect on the Company’s business and results of operations.

THE COMPANY FACES INCREASED RISKS OF INTERNATIONAL OPERATIONS

International sales have accounted for over 20% of the Company’s sales for each of the past three years and may increase over time. International sales are subject to a number of risks, including the following:

•		fluctuations in exchange rates may affect the demand for products and services the Company provides in foreign markets

•		adverse changes in local economic conditions could depress the demand for the Company’s products

•		agreements may be difficult to enforce and receivables difficult to collect through a foreign country’s legal system

•		foreign customers may have longer payment cycles

•		foreign countries may impose additional withholding taxes or otherwise tax the Company’s foreign income, impose tariffs, or adopt other restrictions on foreign trade

•		U.S. export licenses may be difficult to obtain

•		the protection of intellectual property in foreign countries may be more difficult than in the United States

•		acts of terrorism or war may have an adverse impact on foreign markets

Any of these factors could have a material adverse impact on the Company’s business and results of operations.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company’s sales are primarily denominated in U.S. dollars and as a result, the Company has relatively little exposure to foreign currency exchange risk with respect to its sales. The Company does not currently hedge against exchange foreign currency rate fluctuations. The effect of an immediate 10% change in exchange rates would not have a material impact on the Company’s future operating results or cash flows.

The Company’s exposure to market risk for a change in interest rates relates primarily to its investment portfolio. As of December 31, 2002, the Company’s short-term investments consisted of available-for-sale securities of $26.3 million. These fixed income marketable securities included corporate bonds, municipal bonds and mutual bond funds, all of which are of high investment grade. These securities are subject to interest rate risk and will decline in value if the market interest rates increase. If the market interest rates were to increase immediately and uniformly by 10% from levels as of December 31, 2002, the decline in the fair value of the portfolio would not be material to the Company’s financial position.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures. Regulations under the Securities Exchange Act of 1934 require public companies to maintain “disclosure controls and procedures,” which are defined to mean a company’s controls and other procedures that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. The Company’s chief executive officer and chief financial officer, based on their evaluation of the effectiveness of its disclosure controls and procedures within 90 days before the filing date of this report, concluded that the Company’s disclosure controls and procedures were effective for this purpose.

Changes in Internal Controls. There were no significant changes in the Company’s internal controls or, to the Company’s knowledge, in other factors that could significantly affect these controls subsequent to the date of the evaluation referenced above.

PART II — OTHER INFORMATION

ITEM 1: LEGAL PROCEEDINGS:

1.) The Company’s medical device subsidiary, Invivo Research, was one of two third-party defendants named in a lawsuit in June of 1994 by Southern Nevada Surgical Center and Surgex Southern Nevada, Inc. in Nevada State District Court. The underlying action in this matter stemmed from an incident involving a surgical patient undergoing a procedure at the Southern Nevada Surgical Center. The patient suffered a serious permanent brain injury. A lawsuit was filed on behalf of the patient against the surgical center and the anesthesiologist who monitored the patient. The defendants in that action made a substantial settlement to the patient. Southern Nevada Surgical Center (“SNSC”) and Surgex were seeking indemnity and contribution of approximately $14 million from the manufacturer of the anesthetic gas machine and Invivo Research, which manufactured the vital signs monitor used in this procedure. SNSC and Surgex alleged that both the anesthetic gas machine and the vital signs monitor were defective. The Company believes that the vital signs monitor operated properly and was properly designed for its intended function and intends to defend itself vigorously in this matter.

In December of 2002, the Company’s insurer agreed to globally settle the U.S. District Court action and Nevada District Court action for an amount within the insurance policy ‘s applicable limits.

In January of 2003, the U.S. District Court granted a Motion for Summary Judgment, which had been filed by the Company in October 2002, and the matter was dismissed. It is believed that CNA will appeal the dismissal.

2.) In November, 1999, four individuals previously employed by the Company’s Invivo Research subsidiary filed a multi-plaintiff lawsuit against the Company in the Middle District Court of Florida alleging violations of the Age Discrimination in Employment Act. Since this filing, three additional individuals have chosen to “opt-in” to this case, one of the individuals has subsequently voluntarily dismissed all claims with prejudice and a second individual has filed a voluntary motion for dismissal from the case. The remaining plaintiffs are claiming entitlement to back pay and front pay in an aggregate amount of approximately $3 million. If they are successful, they would be also be entitled to liquidated (double) damages with respect to back pay, to their attorneys’ fees and costs and to prejudgment interest. The Company believes that Invivo Research has substantial defenses to the plaintiffs’ allegations and intends to defend itself vigorously in this matter. The Company further believes that even if the plaintiffs were successful in pursuit of their claims, that the proper amount of damages would be substantially less than the amount alleged. The trial in this matter is currently set to begin in the second quarter of 2003.

ITEM 2: CHANGES IN SECURITIES:


	Not Applicable.

ITEM 3: DEFAULTS UPON SENIOR SECURITIES:


	Not Applicable.

ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITIES HOLDERS:


	At the Annual Meeting of Stockholders of the Company held on December 12, 2002, the Company’s stockholders:


	1. Elected all the nominees to serve on the Company’s Board of Directors for the ensuing year as follows:


					ABSTAIN/BROKER
NAME	FOR		AGAINST/WITHHELD		NON-VOTES

James B. Hawkins		3,236,015		20		416,910
Ernest C. Goggio		3,294,915		20		358,010
George S. Sarlo		3,295,015		20		357,910
Laureen DeBuono		3,294,015		20		358,910


	2. Amended the 1994 Stock Option Plan (the “Plan”) to increase by 100,000 shares the number of shares of the Company’s common stock subject to options that may be granted under the Plan. The votes for amending the Plan were as follows:


FOR	AGAINST/WITHHELD		ABSTAIN/BROKER NON-VOTES

2,876,668		639,317		136,960


	3. Ratified the selection of KPMG LLP as independent auditors for the Company. The votes for ratifying the selection of KPMG LLP were as follows:


FOR	AGAINST/WITHHELD		ABSTAIN/BROKER NON-VOTES

3,579,075		43,020		30,850

ITEM 5: OTHER INFORMATION:


	Not Applicable.

ITEM 6: EXHIBITS AND REPORTS ON FORM 8-K

	(a)		Exhibit 99.1-Certification of chief executive officer and chief financial officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002

			Exhibit 10.04 — Loan Agreement between Invivo Corporation and Wells Fargo Bank dated January 1, 2003

	(b)		Reports on Form 8-K:

			None.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	INVIVO CORPORATION


Date: February 14, 2003	By:	/s/ JOHN F. GLENN Vice President of Finance and Chief Financial Officer (Principal Financial and Accounting Officer)

CHIEF EXECUTIVE OFFICER CERTIFICATION

I, James B. Hawkins, President and Chief Executive Officer of Invivo Corporation, certify that:

1.		I have reviewed this quarterly report on Form 10-Q of Invivo Corporation (the “Registrant”);

2.		Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.		Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this quarterly report.

4.		The Registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Registrant and we have:

			a.) Designed such disclosure controls and procedures to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

			b.) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and

			c.) Presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

The Registrant’s other certifying officers and I have disclosed, based on our most recent evaluation, to the Registrant’s auditors and the audit committee of Registrant’s board of directors (or persons performing the equivalent function):

			a.) All significant deficiencies in the design or operation of internal controls which could adversely affect the Registrant’s ability to record, process, summarize and report financial data and have identified for the Registrant’s auditors any material weaknesses in internal controls; and

			b.) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal controls; and

The Registrant’s other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.


Date:		February 14, 2003

By:		/s/ JAMES B. HAWKINS James B. Hawkins President and Chief Executive Officer

CHIEF FINANCIAL OFFICER CERTIFICATION

I, John F. Glenn, Vice President of Finance and Chief Financial Officer of Invivo Corporation, certify that:

1.		I have reviewed this quarterly report on Form 10-Q of Invivo Corporation (the “Registrant”);

2.		Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.		Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this quarterly report.

4.		The Registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Registrant and we have:

			a.) Designed such disclosure controls and procedures to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

			b.) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and

			c.) Presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

			a.) All significant deficiencies in the design or operation of internal controls which could adversely affect the Registrant’s ability to record, process, summarize and report financial data and have identified for the Registrant’s auditors any material weaknesses in internal controls; and

			b.) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal controls; and


Date:		February 14, 2003

By:		/s/ JOHN F. GLENN John F. Glenn Vice President of Finance and Chief Financial Officer

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents